Levi & Korsinsky, LLP announces that an ACAD class action lawsuit has been filed on behalf of investors who purchased Acadia Pharmaceuticals Inc. (ACAD) securities between June 15, 2020, and April 4, 2021. For more on the ACAD Lawsuit please contact us today.

According to the Acadia lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE ACAD CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Acadia you have until June 18, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com